{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-NNMZTYZ3/ec0d720d-91b2-4c31-9e00-e6c385b3e3ab/PDF","dcterms:extent":"175 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-NNMZTYZ3/8901cb3f-b962-433d-a35c-5bcaa0126f19/TEXT","dcterms:extent":"39 KB"}],"edm:TimeSpan":{"@rdf:about":"1929-2026","edm:begin":{"@xml:lang":"en","#text":"1929"},"edm:end":{"@xml:lang":"en","#text":"2026"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-NNMZTYZ3","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/urn:nbn:si:spr-a30mfzkp"},{"@xml:lang":"sl","#text":"Zdravniški vestnik"}],"dcterms:issued":"2013","dc:creator":["Ferk, Polonca","Ornik, Vanja"],"dc:format":[{"@xml:lang":"sl","#text":"številka:7/8"},{"@xml:lang":"sl","#text":"letnik:82"},{"@xml:lang":"sl","#text":"str. 487-496"}],"dc:identifier":["ISSN:1318-0347","COBISSID:512342840","URN:URN:NBN:SI:doc-NNMZTYZ3"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"dc:subject":[{"@xml:lang":"sl","#text":"farmakogenetika"},{"@xml:lang":"sl","#text":"farmakoterapija"},{"@xml:lang":"en","#text":"genetic polymorphisms"},{"@xml:lang":"sl","#text":"genetski polimorfizmi"},{"@xml:lang":"en","#text":"pharmacogenetics"},{"@xml:lang":"en","#text":"pharmacotherapy"},{"@xml:lang":"en","#text":"polycystic ovary syndrome"},{"@xml:lang":"sl","#text":"sindrom policističnih jajčnikov"},{"@xml:lang":"sl","#text":"sladkorna bolezen tipa 2"},{"@xml:lang":"en","#text":"type 2 diabetes"}],"dcterms:temporal":{"@rdf:resource":"1929-2026"},"dc:title":{"@xml:lang":"sl","#text":"Raznolikost v farmakološkem odzivu na zdravljenje z metforminom| Variability in pharmacological response to metformin treatment|"},"dc:description":[{"@xml:lang":"sl","#text":"Background: According to the Slovenian guidelines,metformin, an oral antidiabetic drug, is adrug of choice for the treatment of type 2 diabetes.Additionally, metformin is paving its wayin polycystic ovary syndrome (PCOS) treatment,although the drug has not (yet) been officially indicatedto treat PCOS. Studies have shown thatmetformin improves clinical and biochemicalfeatures of PCOS as well as the rate of ovulationand consequently the likelihood of conceptionin PCOS women. At the same dosage regimen,pharmacological effects of metformin show interindividualvariability in metformin response;efforts have been made to at least partly explainthe variability with polymorphic variants ingenes related to metformin pharmacodynamicsand pharmacokinetics.Conclusions: The results of the current studiesindicate that polymorphic variants in genesrelated to metformin pharmacodynamics andpharmacokinetics may contribute to the interindividualvariability in pharmacological responseto metformin treatment in diabetic as well as inPCOS patients"},{"@xml:lang":"sl","#text":"Izhodišča: Metformin je peroralni antidiabetik in je po slovenskih smernicah zdravilo prve izbire za zdravljenje sladkorne bolezni tipa 2 (SB2). Svoje mesto si utira tudi pri zdravljenju sindroma policističnih jajčnikov (PCOS), čeprav PCOS (še) ni uradno med indikacijami za zdravljenje z metforminom. Študije kažejo, da metformin izboljša klinično in biokemično sliko PCOS ter zveča stopnjo ovulacije in s tem verjetnost za zanositev pri ženskah s tem sindromom. Farmakološki učinki metformina se ob enakem režimu odmerjanja med bolniki razlikujejo, kar poskušamo med drugim razložiti tudi z vplivom polimorfnih različic v genih, povezanih s farmakodinamiko in farmakokinetiko metformina.Zaključki: Rezultati raziskav kažejo, da polimorfne različice v genih, povezanih s farmakodinamiko in farmakokinetiko metformina, lahko prispevajo k raznolikosti v odzivu na zdravljenje z metforminom tako pri bolnikih s SB2 kot pri bolnicah s PCOS"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-NNMZTYZ3","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-NNMZTYZ3"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-NNMZTYZ3/ec0d720d-91b2-4c31-9e00-e6c385b3e3ab/PDF"},"edm:rights":{"@rdf:resource":"http://creativecommons.org/licenses/by-nc/4.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-NNMZTYZ3/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-NNMZTYZ3"}}}}